An estimated 828 million adults (420 women, 408 men) had diabetes in 2022, an increase of 630 million since 1990. India (212 ...

Eli Lilly (LLY) files lawsuit against U.S. health agency over 340B Program rebates, alleging arbitrary blockage of its cash ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Lilly follows fellow drugmaker Johnson & Johnson, who sued the Health and Human Services Department on Tuesday, accusing the ...

Wolfe Research initiated coverage of Eli Lilly (LLY) with an Outperform rating and $1,000 price target The company has lost over $100B in ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation and aggregation into neurofibrillary tangles (right). [Courtesy of Eli ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Three stocks that have not only been around for a century but have also been paying dividends for that long are Coca-Cola ...

The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...

Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...